Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample

LettersApril 2023Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter-2 Inhibitors in a National Population-Based SampleShichao Tang, PhD, Hui Shao, PhD, Mohammed K. Ali, MD, Ping Zhang, PhDShichao Tang, PhDDivision of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GeorgiaSearch for more papers by this author, Hui Shao, PhDDepartment of Family and Preventive Medicine, School of Medicine, and Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GeorgiaSearch for more papers by this author, Mohammed K. Ali, MDDepartment of Family and Preventive Medicine, School of Medicine, and Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GeorgiaSearch for more papers by this author, Ping Zhang, PhDDivision of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GeorgiaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M22-3051 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: The 2022 consensus report from the American Diabetes Association and European Association for the Study of Diabetes recommended using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among persons with type 2 diabetes (T2D) who have established or are at high risk for atherosclerotic cardiovascular disease (ASCVD), and using sodium–glucose cotransporter-2 inhibitors (SGLT2is) among those with T2D who have established ASCVD, chronic kidney disease, or heart failure or are at high risk for ASCVD (level A evidence) (1).Objective: To estimate, using nationally representative data, the number and percentage of persons with T2D who would meet the recommended criteria and were ...References1. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753-2786. [PMID: 36148880] doi:10.2337/dci22-0034 CrossrefMedlineGoogle Scholar2. Nargesi AA, Jeyashanmugaraja GP, Desai N, et al. Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus. J Am Heart Assoc. 2021;10:e021084. [PMID: 33998258] doi:10.1161/JAHA.121.021084 CrossrefMedlineGoogle Scholar3. Mahtta D, Ramsey DJ, Lee MT, et al. Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the Department of Veterans Affairs. Diabetes Care. 2022;45:372-380. [PMID: 35015080] doi:10.2337/dc21-1815 CrossrefMedlineGoogle Scholar4. Hong D, Si L, Jiang M, et al. Cost effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review. Pharmacoeconomics. 2019;37:777-818. [PMID: 30854589] doi:10.1007/s40273-019-00774-9 CrossrefMedlineGoogle Scholar5. Choi JG, Winn AN, Skandari MR, et al. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. A cost-effectiveness study. Ann Intern Med. 2022;175:1392-1400. [PMID: 36191315] doi:10.7326/M21-2941 LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Shichao Tang, PhD; Hui Shao, PhD; Mohammed K. Ali, MD; Ping Zhang, PhDAffiliations: Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GeorgiaDepartment of Family and Preventive Medicine, School of Medicine, and Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GeorgiaDisclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M22-3051.Reproducible Research Statement: Study protocol: Not available. Statistical code: Available from Dr. Tang (e-mail, stang2@cdc.gov). Data set: NHANES is available at www.cdc.gov/nchs/nhanes/index.htm.Corresponding Author: Shichao Tang, PhD, Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Atlanta, GA 30341; e-mail, stang2@cdc.gov.This article was published at Annals.org on 28 February 2023. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics April 2023Volume 176, Issue 4Page: 582-583KeywordsAtherosclerotic cardiovascular diseaseCardiovascular diseasesChronic kidney diseaseDiabetes preventionHealth promotionHeart failurePreventive medicineRenal failureResearch reporting guidelinesType 2 diabetes ePublished: 28 February 2023 Issue Published: April 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...